Oral activity and pharmacokinetics of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in mice

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 1, 2002, Pages 20-26

  Zhao, L ^a   Kestell, P ^a   Ching, L M ^a   Baguley, B C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antivascular; Nitric oxide; Serotonin; Tumour necrosis factor

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; NITRATE; NITRIC OXIDE; SEROTONIN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; COLON TUMOR; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; GROWTH RATE; LIVER; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; CANCER INHIBITION; DISEASE MARKER; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; MAXIMUM TOLERATED DOSE; SEROTONIN RELEASE; TISSUE DISTRIBUTION; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; FEMALE; HALF-LIFE; HYDROXYINDOLEACETIC ACID; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0036137568     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0377-3     Document Type: Article

References (29)

1. Small-molecule cytokine inducers causing tumor necrosis
2. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine - Relation to vascular effects
3. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
4. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)
5. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid
6. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice
7. Induction of STAT and NF kappa B activation by the antitumour agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line
8. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid
9. Evolving role of oral chemotherapy for the treatment of patients with neoplasms
10. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
11. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4acetic acid: A novel approach to cancer therapy
12. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci
13. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethyl-xanthenone-4-acetic acid in mouse, rat and rabbit
14. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-actic acid (DMXAA) in mice by thalidomide
15. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
16. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice
17. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model
18. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid
19. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator to other inducers of tumour necrosis factor
20. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid
21. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution
22. Potential antitumor agents. 61. Structure-activity relationships for in vivo Colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids
23. Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI), in the phase 1 trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
24. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice
25. Combination of the antivascular agent DMXAA with radiation and chemotherapy
26. Enhancement of tumor radiation response by the antivascular agent 5,6-dimentylxanthenone-4-acetic acid (DMXAA)
27. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
28. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents
29. The morphological effects of the anti-tumour agents flavone acetic acid and 5,6-dimethylxanthenone acetic acid on the Colon 38 mouse tumour